Business / Finance

RSS

BDMS revenue increases 2.7% to $16.9M in second quarter 2014

Birner Dental Management Services, Inc.,operators of PERFECT TEETH® dental practices, announced results for the quarter and six months ended June 30, 2014.

13 Aug 2014

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Neovasc Inc. ("Neovasc" or the "Company") today announced financial results for the three months ended March 31, 2014. All results are reported in Canadian dollars unless otherwise stated.

13 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Tackling rising healthcare costs: an interview with Professor Graeme Currie, Warwick Business School

I think the main reason involves the impact of an aging population, some of whom age healthily, but many of whom, unhealthily, particularly those from poorer sectors of society.

12 Aug 2014

ChromaDex reports 42% increase in Q2 2014 net sales

ChromaDex Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.

12 Aug 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year.

12 Aug 2014

Ability Dynamics secures distribution in Canada for RUSH HiPro and RUSH LoPro prosthetic feet

Ability Dynamics, LLC announced today it has secured an exclusive Canadian distribution relationship for its flagship products the RUSH HiPro and the RUSH LoPro prosthetic feet.

12 Aug 2014

Oncothyreon reports decreased net operating loss in Q2 2014

Oncothyreon Inc. today reported financial results for the second quarter ended June 30, 2014. Loss from operations decreased to $7.8 million for the three months ended June 30, 2014 compared with $18.0 million for the comparable period in 2013, and decreased to $15.0 million for the six months ended June 30, 2014 compared with $26.0 million for the comparable period in 2013.

12 Aug 2014

Skilled Healthcare Group Q2 2014 revenue decreases 1.5% to $207 million

Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and six month period ended June 30, 2014.

12 Aug 2014

Mindray net revenues increase 8.9% to $334.5 million in Q2 2014

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2014.

From Mindray 12 Aug 2014

GenoSpace completes financing deal with Thomson Reuters

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it completed a financing deal with Thomson Reuters, the world leader in providing intelligent information for businesses and professionals.

12 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Valeant receives request for additional information from FTC under Hart-Scott-Rodino

Valeant Pharmaceuticals International, Inc. announced that the Company has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Valeant's proposed acquisition of Allergan, Inc.

12 Aug 2014

BIOREM announces 4 new orders totalling $1.5 million

BIOREM Inc. today announced four new orders totalling $1.5 million. The orders include a biogas conditioning system and an odour control system in North America, as well as an industrial VOC/odour abatement system in Asia and a small odour control system in the Middle East.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014